News Releases

Bodisen Biotech Received Contracts Totaling $27.4 Million in January for 2005 Product Delivery
Wednesday February 9, 9:00 am ET

NEW YORK--(BUSINESS WIRE)--Feb. 9, 2005--Bodisen Biotech, Inc., (OTCBB: BBOI, website: /) announced today that in January its total contracts received for 2005 product delivery totaled $27.4 million. This figure does not include any contracts that are likely to be secured in the remaining three quarters of 2005. Bodisen's new customers include a number of large national wholesale distributors that were secured at recent expos, tradeshows and by Bodisen's growing brand name.

Ms. Qiong Wang, CEO of Bodisen, commented "We are very pleased with the new contracts that we have obtained for 2005 delivery. We are now nearing the completion of our new manufacturing facilities which will at least double our current manufacturing capacity in 2005 and allow us to meet the demand already being shown by customers this year."

Utilizing proprietary technologies, Bodisen sells over 60 packaged products in 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.




Bodisen Biotech, Inc.
Investor Relations, 212-566-3503


Source: Bodisen Biotech, Inc.


Copyright © 2004